Analysts Target Netflix, Moderna, and Humana in Week of High-Stakes Calls

A series of high-impact analyst calls moved individual stocks this week, as Wall Street focused on company-specific catalysts ranging from regulatory risks and competitive threats to pivotal clinical trial data and government reimbursement ratings.

Downgrades Hit Netflix, PG&E, and BMW

Analysts took a more cautious stance on several major companies facing significant headwinds. Netflix (NFLX) was downgraded by HSBC from Buy to Hold, with its price target cut by 21% to $76. The bank cited intensifying competition from YouTube and the burden of content spending, which is expected to compress earnings through 2028. The move followed a recent downgrade from Wells Fargo, which highlighted an estimated 8% decline in viewing time per subscriber, signaling broader analyst concern over user engagement.

In the utilities sector, UBS downgraded PG&E Corp (PCG) from Buy to Neutral and slashed its price target to $14 from $19. According to UBS, the downgrade was prompted by a combination of negative factors, including the utility rescinding its long-term EPS guidance and the dwindling prospect of California passing crucial wildfire liability reform this year. The analyst noted that regulatory catalysts for the stock have faded.

German automaker Bayerische Motoren Werke AG (BMW) was also downgraded to Hold from Buy by HSBC. The bank revised its outlook based on a faster-than-expected deterioration in its China business, where it now projects a 25% year-over-year sales decline in 2026. The report noted that German premium brands are losing ground to local Chinese competitors.

Moderna Becomes a Key Battleground Stock

Ad

Moderna (MRNA) became the subject of a sharp Wall Street debate after Rothschild Redburn initiated coverage with a Sell rating and an $81 price target, implying roughly 58% downside from its trading price near $195. The firm's bearish thesis is centered on the view that the stock's valuation has become stretched following a massive year-to-date run-up fueled by optimism over its melanoma vaccine candidate.

The Sell rating stands in stark contrast to recent upgrades to Buy and Peerperform from Argus and Wolfe Research, respectively. This wide divergence in analyst opinion underscores the binary risk surrounding Moderna's upcoming Phase III melanoma trial results, which are seen as the next major catalyst for the stock.

Humana Upgraded Ahead of Medicare Decision

In the week's most impactful upgrade, Barclays analyst Andrew Mok raised Humana (HUM) to Overweight from Equal-weight, lifting the price target by $108 to $515. The stock surged as much as 9% on the news Friday, its largest intraday gain since June.

The upgrade is based on a specific, near-term catalyst: the upcoming Medicare Star ratings release, expected around October 8. Barclays increased its probability to 75% that Humana's key H5216 contract, which covers 2.4 million members, will achieve bonus status. According to the firm, securing this rating could add approximately $1.5 billion to EBIT and $9 to EPS, making the October announcement a critical event for the health insurer's earnings outlook.